Pruksananonda K, Suwajanakorn S, Boonkasemsanti W, Virutamasen P
Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
J Med Assoc Thai. 1999 Jan;82(1):9-14.
The clinical efficacy and side effects of oral gestrinone, 2.5 mg twice weekly, were evaluated in this prospective study involving 22 patients with laparoscopically confirmed endometriosis. All patients came to the hospital with infertility problem. After 6 months of treatment, 81 per cent of patients had amenorrhea. Dysmenorrhea and pelvic pain were reduced from 90.9 per cent to 14.3 per cent and 81.8 per cent to 9.5 per cent respectively. Pelvic tenderness and induration were improved from 55.6 per cent and 50.0 per cent to 15.8 per cent and 10.5 per cent respectively. Androgenic effects such as acne was founded in 18.2 per cent of the patients. Return of fertility was observed in 25 per cent (5 patients) after 30-254 days post treatment. No serious side effect was detected during the treatment. The results suggest that gestrinone may be considered an option for the treatment of endometriosis related infertility.
在这项前瞻性研究中，对22例经腹腔镜确诊为子宫内膜异位症且伴有不孕问题的患者，评估了口服孕三烯酮（每周两次，每次2.5毫克）的临床疗效和副作用。治疗6个月后，81%的患者出现闭经。痛经和盆腔疼痛分别从90.9%降至14.3%，以及从81.8%降至9.5%。盆腔压痛和硬结分别从55.6%和50.0%改善至15.8%和10.5%。18.2%的患者出现了如痤疮等雄激素样作用。治疗后30 - 254天，25%（5例患者）观察到恢复生育能力。治疗期间未检测到严重副作用。结果表明，孕三烯酮可被视为治疗子宫内膜异位症相关性不孕的一种选择。
